C-PEPTIDE AND CARDIOVASCULAR DISEASES

Deepika Loona, Sukhraj Kaur, Pashaura Singh Sandhu

Abstract


Introduction: Cardiovascular diseases (CVD) are a major cause of death and disability throughout the world. This group of disorders is preceded by atherosclerosis which is usually the underlying pathology and develops many years earlier to the time the symptoms occur. Although many molecules have been considered, C-peptide has been shown to play a major role in atherogenesis.

Aim: The present study was thus planned to study the role of C-peptide in various cardiac disorders.

Material and Methods: The study comprised of 100 patients of various cardiac disorders and 100 apparently healthy normal individuals served as controls. All the subjects were investigated for baseline parameters i.e. Fasting plasma glucose, Glycated hemoglobin, Lipid profile and C-peptide. Body Mass Index was also calculated.

Results: Body Mass Index increased significantly in male patients as compared to controls (p<0.05). Both Fasting plasma glucose and Glycated hemoglobin along with Total cholesterol, Triglycerides, Low Density Lipoprotein-Cholesterol, Very Low Density Lipoprotein-Cholesterol increased significantly (p<0.05) in both male and female patients as compared to controls whereas High Density Lipoprotein-Cholesterol decreased highly significantly (p<0.001) in female patients as compared to controls whereas change in male patients was significant (p<0.05). The HDL-C: LDL-C ratio was atherogenic in these individuals. Levels of C-peptide also increased significantly (p<0.001) in patients with cardiac disorders as compared to normal individuals.

Conclusion: C-peptide once deposited in the sub endothelial space may promote inflammation and lower High Density Lipoprotein-Cholesterol levels, thus it can be postulated that increased levels of C-peptide are associated with cardiac disorders.


Keywords


Lipid profile, Atherosclerosis, C-peptide

Full Text:

PDF

References


Verma AS, Singh A. Animal Biotechnology: Models in discovery and translation. 1st ed. Oxford, UK: Elsevier; 2014.

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics 2018 update report from American Heart Association. Circulation 2018;137:e67-492.

Lazzeri C, Valente S, Dalfonso MG, Chiostri M, Gensini GF. Determinants of C-peptide levels and acute insulin resistance/sensitivity in non-diabetic STEMI role of killip class. IJC Metabolic & endocrine. 2014;2:35-38.

Caterina RD, Madonna R, Sourij H, Wascher T. Glycaemic control in Acute Coronary Syndromes: prognostic value and therapeutic options. European heart journal. 2010;31: 1557-1564.

Farhan S, Jarai R, Tentzeirs I, Freynhofer MK, Brozovic I, Vogel B,et al. Admission proinsulin is associated with mortality in patients with admission hyperglycemia during Acute Coronary Syndrome: results from a pilot observational study.Clinical Chemistry. 2011; 57(10):1456-1460.

Leon ACD, Garcia JGO, Rodriguez IM, Gonzalez DA, Sanchez JJE, Diaz BB, et al. C-peptide as a risk factor of Coronary Artery Disease in the general population. Diabetes & vascular disease research. 2015;12(3):199-207.

Marx N, Walcher D. C-peptide and Atherogenesis: C-peptide as a mediator of lesion development in patients with type 2 diabetes mellitus. Experimental diabetes research. 2008; article Id 385108.

Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, et al. C-peptide induces vascular smooth muscle cell proliferation: involvement of Src-kinase, phosphatidylinositol 3-kinase and extracellular signal-regulated kinase ½. Circ Res. 2006;99(11):1181-1187.

Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J. 2006;82(968):357-362.

Kim ST, Kim BJ, Lim DM, Song IG, Jung JH, Lee KW, et al. Basal C-peptide level as a surrogate marker of subclinical atherosclerosis in type 2 diabetic patients. Diabetes Metab J. 2011;35(1):41-9.

Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann ClinBiochem. 1969;6:24-27.

Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med. 1971;284(7):353-7.

Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry. 1994;1003-1008.

Stein EA, Myers GL. Lipids, Lipoproteins and Apolipoproteins in Tietz Textbook of Clinical Chemistry.1994;1002-93.

Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11(6):583-95.

Ragland BD, Konrad RJ, Chaffin C, Robinson CA, Hardy RW. Evaluation of a homogenous direct LDL-cholesterol assay in diabetic patients: effect of glycemic control. Clin Chem. 2000;46(11):1848-51.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.

Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin treated diabetics. Diabetes. 1977;26(1):22-9.

Bahuleyan CG. Hospital data on coronary artery disease from North Kerala. 1996;54-9.

Girija G. Risk factors profile of patients with acute MI. 1996:78-83.

Waist-hip ratio as a predictor of myocardial infarction risk. Medicine (Baltimore). 2018; 97(30):e11639.

Rissam HS, Kishore S, Trehan N. Coronary Artery Disease in Young Indians- The Missing Link. Indian Academy of Clinical Medicine J. 2001;2(3):128-32.

Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95(1):69-75.

Drexel H, Amann F, Beran J, Rentsch K, Candinas R, Muntwyler J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994;90(5):2230-2235.

Assmann G, Schulte H, Funke H, Von Eckardstein A. The Emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19 Suppl M:M8-14.

Manninen V, Tenkanen L, Koshinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85(1):37-45.

Grundy SM. Small LDL, Atherogenic dyslipidemia and the metabolic syndrome. Circulation. 1997;95(1):1-4.

Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF. The metabolism of proinsulin and insulin by the liver. J Clin Invest. 1972;51(4):912–921.

Matthews DR, Rudenski AS, Burnett MA, Darling P, Turner RC. The half-life of endogenous insulin and C-peptide in man assessed by somatostatin suppression. ClinEndocrinol (Oxf). 1985;23(1):71–9.

Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157(1):75–83.


Refbacks

  • There are currently no refbacks.